Axsome Therapeutics, Inc. researches, develops, and commercializes treatments for highly prevalent neurological and psychiatric illnesses. The company's commercial portfolio includes Auvelity for major depressive disorder, Sunosi for excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and Symbravo for the acute treatment of migraines. Beyond its marketed products, Axsome advances a robust clinical pipeline featuring late-stage candidates like AXS-05 for Alzheimer's disease agitation and smoking cessation, as well as AXS-12 for narcolepsy. The company primarily generates revenue through prescription drug sales within the U.S. healthcare system. By focusing on small-molecule therapies that address significant unmet medical needs, Axsome bridges the gap between clinical-stage research and commercial pharmaceutical distribution.
